Patient communication platform Artera, formerly Well Health, announced it has partnered with GPT-enabled conversational AI provider Hyro to launch Artera Care Assist, an AI-powered virtual assistant ...

SAN FRANCISCO, June 04, 2026--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, today announced the clinical ...

SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, today announced the first patient enrollment in ...

Artera Harmony Federal Edition Meets FedRAMP Security Requirements and Is Granted an Authority to Operate, Allowing the Company to Expand on Today's Deep Partnerships with Federal Healthcare Agencies ...

SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, and Tempus, a technology company leading the adoption ...

Artera has obtained US Food and Drug Administration (FDA) clearance for ArteraAI Breast, making it the first digital pathology–based risk stratification tool for breast cancer to receive clearance ...

Validation of MMAI in node-positive HR+ breast cancer to determine chemotherapy benefit Concordance analysis between MMAI and 21-gene Recurrence Score test in breast cancer Artera, the developer of ...

The MarketWatch News Department was not involved in the creation of this content. Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, will ...

(formerly WELL Health), a SaaS digital health leader in patient communications, recently welcomed Karri Alexion-Tiernan as VP of Product Marketing, Joanne Chen as VP of Data and Mark Thomson as VP of ...

California-based Artera, a company that develops multimodal AI-based prognostic and predictive cancer tests, has been granted de novo authorization by the FDA for its AI tool for prostate cancer ...

Artificial intelligence specialist Artera has won FDA approval for AI-powered software that can help guide the management of patients diagnosed with localised prostate cancer. ArteraAI Prostate is ...

First digital pathology-based test to provide individual risk estimates to help inform treatment planning in mHSPC Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic ...